KBR, Inc. ( KBR Quick Quote KBR - Free Report) reported impressive results for fourth-quarter 2020, wherein earnings topped the Zacks Consensus Estimate. Also, earnings and revenues increased year over year. However, following the announcement, shares of the company dropped 0.8% during trading hours on Feb 22.
During the quarter, the company completed the acquisition of Centauri, accelerating growth in critical national security missions and strengthening its position as a provider of high-end, digitally-enabled solutions as well as technologies in attractive end markets.
Inside the Headline Numbers
Adjusted earnings of 51 cents per share surpassed the consensus estimate of 48 cents by 6.3%. The reported figure increased 10.9% from 46 cents per share reported a year ago.
Total revenues improved 1% year over year to $1,466 million. However, the top line missed the consensus estimate of $1,509 million by 2.8%.
Adjusted EBITDA increased 15.4% year over year to $135 million in the quarter. Adjusted EBITDA margin improved 110 bps (basis points) on year over year to 9.2%.
Revenues in the Government Solutions segment inched up 14.4% year over year to $1,074 million. The upside is attributable to solid space and defense systems engineering businesses. Adjusted EBITDA margin of 9.3% contracted 160 bps year over year.
Technology Solutions' revenues decreased 23.7% year over year to $71 million due to higher concentration of license mix. That said, adjusted EBITDA margin contracted to 26.8% from 31.2% a year ago.
Energy Solutions' revenues decreased 23.6% year over year to $321 million. That said, adjusted EBITDA margin of 5.3% increased 220 bps from the year-ago level on cost-control measures.
As of Dec 31, 2020, total backlog came in at $15.12 billion compared with $14.64 billion at 2019-end. Of the total backlog, Government Solutions booked $12.53 billion. Technology Solutions and Energy Solutions segments accounted for $704 million and $1.89 billion of the total backlog, respectively.
Government and Technology Solution units had a book-to-bill ratio of 1.2 and 1.4, respectively, excluding the impact of long-term privately-financed initiatives or PFIs.
As of Dec 31, 2020, KBR’s cash and cash equivalents were $436 million, down from $712 million at 2019-end. Long-term debt was $1.58 billion versus $1.18 billion at 2019-end.
For 2020, cash provided by operating activities totaled $367 million compared with $256 million in 2019. Adjusted operating cash flow was $290 million, up from $256 million a year ago.
Total revenues in 2020 came in at $5,767 million compared with $5,639 million in 2019, showing a 2.3% increase.
Adjusted EBITDA increased 1.5% to $478 million in 2020, mainly on revenue growth.
Earnings per share grew 2.4% year over year to $1.73.
For 2021, the company expects total revenues in the range of $5.8-$6.2 billion and an adjusted EBITDA margin of 9%. Also, it expects effective tax rate between 25% and 26% and adjusted earnings per share in the band of $2.00-$2.20.
Meanwhile, operating cash flow is projected in the range of $250-$290 million, while adjusted operating cash flow is estimated between $280 million and $320 million.
Meanwhile, for 2021, KBR updated the names of its businesses to Government Solutions (that comprises four business units, namely, Defense & Intel, Science & Space, and Readiness & Sustainment), and Sustainable Technology Solutions (formerly called Technology Solutions) to better reflect its business portfolio of advanced technologies.
KBR — which shares space with
AECOM ( ACM Quick Quote ACM - Free Report) and Jacobs Engineering Group Inc. ( J Quick Quote J - Free Report) and Quanta Services Inc. ( PWR Quick Quote PWR - Free Report) in the Zacks Engineering - R and D Services industry — currently carries a Zacks Rank #3 (Hold). You can see . the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better. See these 7 breakthrough stocks now>>